Recombinant Human CD19 Protein Summary
Recombinant Protein
CD19
Applications/Dilutions
In Vitro Wheat Germ System + Liposome Technology offers significant advantages over commonly used protein expression platforms:
Higher Yield
Greater Stability
High Expression Success Rate
Native Protein Conformation
This protein has not yet been tested for use in functional studies and/or compound screening.
All experiments requiring biological activity of the protein will not be backed by the Novus Guarantee or be eligible for the Innovators Reward™ and must be undertaken at the customers own risk.
Packaging, Storage & Formulations
Store at -80C. Avoid freeze-thaw cycles.
Liquid: 25 mM Tris-HCl of pH8.0 containing 2% glycerol.
Notes
Peptide Sequence: PPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTRThis product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for Recombinant Human CD19 Protein
- B4
- B-lymphocyte antigen CD19
- B-lymphocyte surface antigen B4
- CD19 antigen
- CD19 molecule
- CD19
- CVID3
- Differentiation antigen CD19
- Leu-12
- MGC12802
- T-cell surface antigen Leu-12
Background
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It is expressed on approximately 10% of normal human peripheral blood cells and approximately 60% of splenic lymphocytes. It is not expressed on granulocytes, monocytes or T cells as defined by CD3 expression. CD19 defines a pan B antigen which is expressed from the earliest stages of B progenitor development, but is lost on terminal differentiation to plasma cells. It may also be present on some early myeloid progenitors, particularly those of the monoblastic type. The CD19 antigen is expressed on approximately 12% of peripheral blood lymphocytes. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.
product targets : SRPK inhibitors